Молодежный инновационный вестникМолодежный инновационный вестник2415-7805Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации11337Conference ProceedingsMonitoring antiplatelet therapy in real clinical practiceMurashkinaAlexandra Alekseevna<p>Assistant Professor of the Department of Clinical Pharmacology and Pharmacotherapy, first-year resident in clinical laboratory diagnostics</p>RayOfSun494@gmail.comhttps://orcid.org/0000-0002-4708-5203KhomichMaria Konstantinovna<p>Laboratory assistant at the Department of Clinical Pharmacology and Pharmacotherapy, first-year resident in clinical pharmacology</p>kkulikovamaria@yandex.ruhttps://orcid.org/0009-0001-6094-9336VorobyevaNadezhda Alexandrovna<p>Grand PhD in Medical sciences, professor, Head of the Department of Clinical Pharmacology and Pharmacotherapy</p>nadejdav0@gmail.comhttps://orcid.org/0000-0001-6613-2485Northern State Medical University0110202615S12022042702202605042026Copyright © 2026, Murashkina A.A., Khomich M.K., Vorobyeva N.A.2026<p style="text-align: justify;">Long-term antiplatelet therapy is a key element in the prevention of cardiovascular complications; however, its efficacy and safety need to be monitored. The aim of the study was to evaluate these parameters taking into account concomitant pharmacotherapy. Material and methods. This retrospective study enrolled 67 patients aged 39 to 91 years (Me 63 [54; 73]), hospitalized at the E.E. Volosevich City Clinical Hospital Hospital in 20242025. Residual platelet reactivity (RPT) was assessed using the VerifyNow point-of-care aggregometry system (ARU for aspirin, PRU for P2Y12 receptor inhibitors). Results. The therapeutic range was achieved for ARU (550) in 87.8% of patients and for PRU (95208) in 59.1% of patients. Stent thrombosis was recorded in two cases (during aspirin therapy, ARU = 475, and during clopidogrel therapy, PRU = 118). Hemorrhagic syndrome was observed more frequently with P2Y12 inhibitors (14 cases) than with aspirin (3 cases). Statistically significant drug-drug interactions were identified: concomitant use of P2Y12 inhibitors with proton pump inhibitors (PPIs) led to an increase in PRU (p = 0.012), while concomitant use of beta-blockers with aspirin led to a decrease in ARU (p = 0.032). A correlation was found between the PPI dose and PRU values (r<sub>s</sub> = 0,281; p = 0,045), as well as between the beta-blocker dose and ARU values (r<sub>s</sub> = 0,283; p = 0,039). Conclusion. Monitoring RPT and accounting for drug-drug interactions enable treatment personalization and reduce the risk of complications.</p>antiplatelet therapyresidual platelet reactivitydrug-drug interactionsантитромбоцитарная терапияостаточная реактивность тромбоцитовмежлекарственные взаимодействия[Лукьянец, К. Ю. Резистентность к терапии препаратами ацетилсалициловой кислоты: факторы риска, механизмы, методы диагностики / К. Ю. Лукьянец, И. Ю. Пчелин // Juvenis Scientia. – 2020. – Т. 6, № 2. – С. 16-34. – DOI 10.32415/jscientia_2020_6_2_16-34. – EDN SPYAAX.][Трухан, Д. И. Кардиоваскулярный риск при длительном применении ингибиторов протонной помпы: миф или реальность / Д. И. Трухан, С. Н. Филимонов // Consilium Medicum. – 2024. – Т. 26, № 1. – С. 55-60. – DOI 10.26442/20751753.2024.1.202532. – EDN MWSTPO.][Носительство аллелей гена CYP2C19 и возможные межлекарственные взаимодействия у пациентов с ишемической болезнью сердца / Н. А. Воробьева, Д. Д. Комиссарова, А. С. Воронцова, П. А. Ветошкина // Рациональная фармакотерапия в кардиологии. – 2025. – Т. 21, № 6. – С. 585-591. – DOI 10.20996/1819-6446-2025-3213. – EDN YFECLK.][Шараева А.Т., Зурдинова А.А., Сатыбалдиева А.Т. Мониторинг и оценка безопасности межлекарственных взаимодействий у пациентов пожилого возраста. Качественная клиническая практика. 2024;(2):52-65. https://doi.org/10.37489/2588-0519-2024-2-51-64. EDN: RROUYQ]